Clinical Trials Sponsored by Research Insight LLC

Total 1917 results

Janssen Research & Development, LLC

Completed

A Study to Evaluate the Effect of Hepatic Impairment on Lazertinib (JNJ-73841937)

Healthy | Hepatic Impairment

Germany
Janssen Research & Development, LLC

Completed

A Thorough QT Study of Aticaprant (JNJ-67953964) in Healthy Adult Participants

Healthy

Belgium
Janssen Research & Development, LLC

Active, not recruiting

An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer

Urothelial Cancer

United States, France, Germany, United Kingdom, Belgium, Taiwan, Spain, Israel, India, Romania, Korea, Republic of, Russian Federation, Turkey, Austria, Moldova, Republic of
Janssen Research & Development, LLC

Terminated

Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus Infection

Respiratory Syncytial Virus Infections

United States, Taiwan, Belgium, Hungary, Thailand, United Kingdom, Germany, Korea, Republic of, Bulgaria, Turkey, France, Italy, Poland, Spain, Brazil, Russian Federation, Japan, Argentina, Malaysia, Mexico, Sweden, South Africa
Janssen Research & Development, LLC

Active, not recruiting

An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies (Galahad)

Prostatic Neoplasms

United States, Australia, France, United Kingdom, Belgium, Taiwan, Spain, Israel, Netherlands, Sweden, Korea, Republic of, Canada, Russian Federation, Brazil, Denmark
Janssen Research & Development, LLC

Completed

A Study of Cetrelimab in Participants With Chronic Hepatitis B Virus Infection

Hepatitis B, Chronic

France, Germany, Spain, Poland, Belgium
Janssen Research & Development, LLC

Completed

A Study to Determine the Abuse Potential of Seltorexant Compared to Suvorexant and Zolpidem

Healthy Non-dependent, Recreational Sedative Users | Abuse Potential

United States
Janssen Research & Development, LLC

Terminated

A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection (PREVENT-HD)

Coronavirus Disease 2019 (COVID-19)

United States
Janssen Research & Development, LLC

Completed

A Study of JNJ-77474462 in Healthy Participants

Healthy

Australia
Janssen Research & Development, LLC

Completed

A Study of Paliperidone Palmitate 6-Month Formulation

Schizophrenia

Hong Kong, Poland, Argentina, Russian Federation, Ukraine, Italy
Janssen Research & Development, LLC

Completed

A Study of JNJ-73763989, JNJ-56136379, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection (PENGUIN)

Hepatitis B, Chronic

Taiwan, Poland, Japan, New Zealand
Janssen Research & Development, LLC

Terminated

A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC)

Prostatic Neoplasms

United States, Canada
Janssen Research & Development, LLC

Completed

A Pharmacokinetic Study of Ustekinumab in Pediatric Subjects With Moderately to Severely Active Crohn's Disease (STELARA)

Crohn Disease

United States, Belgium, Canada, France, Poland, Germany
Janssen Research & Development, LLC

Completed

A Study to Investigate the Safety of the Drugs Topiramate and Levetiracetam in Treating Children Recently Diagnosed With Epilepsy

Epilepsy

United States, France, Poland, Taiwan, Argentina, South Africa, Belgium, Germany, Russian Federation, Austria, Hungary, Canada, Philippines, Australia
Janssen Research & Development, LLC

Completed

A Phase 1b Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of JNJ-64565111 in Participants With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Effect of Hepatic Impairment on JNJ-42847922 in Adult Participants

Healthy | Hepatic Impairment

Germany
Janssen Research & Development, LLC

Completed

A Study to Identify Participants With Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations

Urothelial Cancer | Receptors, Fibroblast Growth Factor

United States, Italy, Belgium, United Kingdom, Japan, Turkey, Brazil, Ukraine, Spain, Russian Federation, Israel, France, Germany, Argentina
Janssen Research & Development, LLC

Completed

Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease (TRIDENT)

Crohn Disease

United States, France, Poland, Ukraine, Germany, Belgium, Bulgaria, Romania, Japan, Canada, Korea, Republic of, Russian Federation, Hungary, United Kingdom
Janssen Research & Development, LLC

Completed

A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes (T1GER)

Diabetes Mellitus, Type 1

United States
Janssen Research & Development, LLC

Terminated

A Study Evaluating Participants With Moderately to Severely Active Crohn's Disease (PRISM)

Crohn Disease

United States, Italy, Ukraine, Poland, Germany, Russian Federation, Argentina
Janssen Research & Development, LLC

Completed

A Study of JNJ-64251330 in Healthy Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 4

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study of TAR-200 in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy

Urinary Bladder Neoplasms

United States, Spain
Janssen Research & Development, LLC

Completed

A Study of JNJ-80202135 in Healthy Chinese Adult Participants

Healthy

China
Janssen Research & Development, LLC

Completed

A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 3

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study of Safety, Pharmacokinetics and Pharmacodynamics of JNJ-64457107 in Participants With Advanced Stage Tumors

Advanced Solid Neoplasms

Spain, Israel
Janssen Research & Development, LLC

Withdrawn

A Study to Assess Feasibility of Using Clinician-directed and Digital Application Supported Cognitive Behavior Therapy (CBT) in Conjunction With Esketamine in Participants With Treatment-resistant Depression

Depression

United States
Janssen Research & Development, LLC

Completed

Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants

Alzheimer Disease

United States
Janssen Research & Development, LLC

No longer available

Pre-approval Access Single Patient Request for Teclistamab (JNJ-64007957)

Multiple Myeloma
Janssen Research & Development, LLC

Terminated

A Study of Guselkumab and Risankizumab in Healthy Participants and Participants With Psoriatic Arthritis

Healthy | Arthritis, Psoriatic

Austria
Janssen Research & Development, LLC

Completed

A Study of Darunavir in the Presence of Cobicistat When Administered as a Fixed Dose Combination Under Fed Conditions

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ-53718678 at Two Dose Levels in Non-Hospitalized Adult Participants Infected With Respiratory Syncytial Virus

Respiratory Syncytial Virus Infections

United States, Taiwan, Japan, Korea, Republic of, France, Mexico, Brazil, Sweden, Argentina, Ukraine, Canada, Spain, Germany, Poland, Belgium, Russian Federation, South Africa, Australia, Bulgaria
Janssen Research & Development, LLC

Completed

A Study of Lazertinib (JNJ-73841937) in Healthy Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study of JNJ-70033093 (Milvexian) in Healthy Adult Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

A Two-Part Infant Study for Early Diagnosis of Respiratory Syncytial Virus (RSV) and Evaluation of JNJ-53718678 in RSV Acute Respiratory Tract Disease

Respiratory Syncytial Viruses

Taiwan, Belgium, United Kingdom, Argentina, Panama
Janssen Research & Development, LLC

Completed

AAVCAGsCD59 for the Treatment of Wet AMD

Wet Age-related Macular Degeneration

United States
Janssen Research & Development, LLC

Completed

A Study to Investigate the Safety, Tolerability, and Pharmacodynamics of JNJ-54175446 in Participants With Major Depressive Disorder

Depressive Disorder, Major

Germany, Netherlands
Janssen Research & Development, LLC

Completed

A Study of 14C JNJ-67953964 in Healthy Adult Male Participants

Healthy

Netherlands
Janssen Research & Development, LLC

Completed

A Study of Bermekimab in Patients With Hidradenitis Suppurativa

Hidradenitis Suppurativa

United States
Janssen Research & Development, LLC

Completed

A Study to Evaluate JNJ-64565111 Pharmacokinetics and Safety in Adult Participants With Varying Degrees of Renal Function

Kidney Failure, Chronic

United States
Janssen Research & Development, LLC

Completed

A Study of Cetrelimab (JNJ-63723283), a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostatic Neoplasms

Canada, Belgium, United States, Spain, Netherlands, Italy, Russian Federation
Janssen Research & Development, LLC

Completed

A Study of Subcutaneously-administered Guselkumab Delivered by 3 Different Devices in Healthy Participants

Healthy

United States, Germany
Janssen Research & Development, LLC

Completed

A Study Exploring the Use of Challenge Agents in Healthy Volunteers or Participants With a Disease of Interest

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study of JNJ-77474462 (Bermekimab) in Healthy Participants of Japanese Descent Following Administration of Single Ascending Subcutaneous Doses

Healthy

Australia
Janssen Research & Development, LLC

Completed

A Study of Sublingually Administered (S)-Ketamine Oral Solution in Healthy Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study to Evaluate SIMPONI (Golimumab) Therapy in Children, Adolescents and Young Adults With Pre-Symptomatic Type 1 Diabetes

Pre-Symptomatic Type 1 Diabetes

United States, Finland, Sweden
Janssen Research & Development, LLC

Completed

A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder

Phobic Disorders

United States, Australia, Canada
Janssen Research & Development, LLC

Completed

A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment (VOYAGE 2)

Psoriasis

United States, Australia, Poland, Germany, Spain, Korea, Republic of, Canada, Russian Federation, Czechia
Janssen Research & Development, LLC

Terminated

A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer (XCITE)

Metastatic Colorectal Cancer

United States, Spain, Australia, Belgium, Israel, Austria, Czechia, United Kingdom, Hungary, Italy, Netherlands, Poland, Switzerland
Janssen Research & Development, LLC

Approved for marketing

Pre-Approval Access With Amivantamab (JNJ-61186372) in Participants With Metastatic Non-Small Cell Lung Cancer

Metastatic Non-Small Cell Lung Cancer

Clinical Trials Sponsored by Research Insight LLC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saint Lucia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations